Prognostic value of primary tumor surgery in seminoma patients with distant metastasis at diagnosis: a population-based study.
- Author:
Sheng-Ming JIN
1
;
Jia-Ming WEI
1
;
Jun-Long WU
1
;
Bei-He WANG
1
;
Hua-Lei GAN
2
;
Pei-Hang XU
1
;
Fang-Ning WAN
1
;
Wei-Jie GU
1
;
Yu WEI
1
;
Chen YANG
3
;
Yi-Jun SHEN
1
;
Ding-Wei YE
1
Author Information
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords: distant metastasis; primary tumor surgery; prognosis; seminoma
- From: Asian Journal of Andrology 2020;22(6):602-607
- CountryChina
- Language:English
- Abstract: The aims of this study were to determine the prognostic value of primary tumor surgery and identify optimal candidates for such surgery among patients with seminoma and distant metastasis at diagnosis. We identified 521 patients with seminoma and distant metastasis at diagnosis between 2004 and 2014 from the Surveillance, Epidemiology, and End Results database. Among these patients, 434 had undergone surgery, whereas 87 had not. The prognostic value of primary tumor surgery was assessed by Kaplan-Meier methods, log-rank analyses, and multivariate Cox's proportional hazards model. Survival curves and forest plots were also plotted. Survival analysis indicated that patients who underwent surgery had a better 5-year overall survival and cancer-specific survival than those who did not. Multivariate analyses demonstrated that primary tumor surgery is an independent prognostic factor for overall survival and cancer-specific survival, along with age at diagnosis, M stage, and marital status. In addition, primary tumor surgery still had considerable prognostic value in the subgroup of patients with lymph node metastasis. Further, forest plots demonstrated that patients with M1a stage, N1 or N2-3 stage, and a younger age at diagnosis (<60 years) may benefit from primary tumor surgery. In conclusion, our findings indicate that primary tumor surgery is correlated with improved survival in patients with seminoma and distant metastasis. Furthermore, primary tumor surgery is an independent prognostic indicator for patients with seminoma and distant metastasis.
